Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs aiming to “reset” the immune systems of people with inflammatory conditions. 

Source link